Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 69.9% in July

Posted by Teresa Graham on Jul 26th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the target of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 27,481 shares, a drop of 69.9% from the June 30th total of 91,267 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average trading volume of 29,455 shares, the short-interest ratio is presently 0.9 days.

Pulmatrix Price Performance

Shares of NASDAQ PULM opened at $1.65 on Friday. The company’s 50 day simple moving average is $1.52 and its 200 day simple moving average is $1.84. Pulmatrix has a fifty-two week low of $1.16 and a fifty-two week high of $5.80. The firm has a market capitalization of $6.02 million, a P/E ratio of -1.34 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Pulmatrix presently has an average rating of “Sell”.

Check Out Our Latest Analysis on Pulmatrix

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC acquired a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).